Albemarle Corporation $ALB Stock Acquired by Phoenix Financial Ltd.

Phoenix Financial Ltd. raised its position in shares of Albemarle Corporation (NYSE:ALB – Free Report) by 1,034.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,429 shares of the specialty chemicals company’s stock after purchasing an additional 15,892 shares during the period. Phoenix Financial Ltd.’s holdings in Albemarle were worth $1,844,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Danske Bank A S increased its stake in shares of Albemarle by 56,770.5% in the 3rd quarter. Danske Bank A S now owns 227,482 shares of the specialty chemicals company’s stock valued at $24,063,000 after purchasing an additional 227,082 shares during the last quarter. Ibex Wealth Advisors acquired a new position in shares of Albemarle during the 3rd quarter worth $289,000. Addison Advisors LLC lifted its position in shares of Albemarle by 126.0% during the 3rd quarter. Addison Advisors LLC now owns 461 shares of the specialty chemicals company’s stock worth $49,000 after buying an additional 257 shares during the last quarter. Aberdeen Group plc lifted its position in shares of Albemarle by 5,344.0% during the 3rd quarter. Aberdeen Group plc now owns 753,618 shares of the specialty chemicals company’s stock worth $79,718,000 after buying an additional 739,775 shares during the last quarter. Finally, Money Concepts Capital Corp lifted its position in shares of Albemarle by 3.7% during the 3rd quarter. Money Concepts Capital Corp now owns 11,280 shares of the specialty chemicals company’s stock worth $1,193,000 after buying an additional 402 shares during the last quarter. 92.87% of the stock is currently owned by institutional investors and hedge funds.

Albemarle Stock Up 0.1%

Shares of NYSE:ALB opened at $93.62 on Monday. The company has a fifty day moving average of $103.61 and a 200-day moving average of $145.56. The company has a market capitalization of $11.05 billion, a PE ratio of 22.61, a price-to-earnings-growth ratio of 0.59 and a beta of 1.34. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.57 and a current ratio of 2.34. Albemarle Corporation has a 52-week low of $89.77 and a 52-week high of $221.00.

Albemarle (NYSE:ALB – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The specialty chemicals company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Albemarle had a return on equity of 14.91% and a net margin of 10.40%. The company had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.52 billion. During the same period in the prior year, the company earned ($0.19) EPS. Albemarle’s revenue was up 18.8% compared to the same quarter last year. On average, equities analysts predict that Albemarle Corporation will post 10.64 EPS for the current fiscal year.

Albemarle Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Friday, December 18th will be issued a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Friday, December 18th. Albemarle’s dividend payout ratio is presently 39.61%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ALB shares. CICC Research raised their price objective on Albemarle from $83.28 to $108.58 in a research note on Wednesday, November 11th. Barclays lowered their target price on Albemarle from $109.00 to $95.00 and set an “equal weight” rating for the company in a research note on Friday, November 6th. Morgan Stanley dropped their target price on shares of Albemarle from $161.00 to $105.00 and set an “equal weight” rating for the company in a report on Monday, November 9th. Wall Street Zen cut shares of Albemarle from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Zacks Research upgraded shares of Albemarle from a “strong sell” rating to a “hold” rating in a research note on Monday, November 9th. Fifteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $152.63.

Get Our Latest Stock Report on ALB

About Albemarle

(Free Report)

Albemarle Corporation is a specialty chemicals company that produces lithium, bromine and refining catalysts. Its products serve industries including energy storage, transportation, electronics, petroleum refining and pharmaceuticals. The company supplies lithium compounds used in rechargeable batteries and other applications. It also makes bromine-based products for uses such as flame retardants and water treatment, along with catalysts used in refining petroleum. Albemarle traces its history to 1887 and is headquartered in Charlotte, North Carolina.

Featured Articles

Want to see what other hedge funds are holding ALB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albemarle Corporation (NYSE:ALB – Free Report).

Institutional Ownership by Quarter for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.